STOCK TITAN
  1. Home
  2. News
  3. INMB

INmune Bio Inc - INMB STOCK NEWS

IMPACT
SENTIMENT
INMB : Nasdaq
INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
clinical trial
IMPACT
SENTIMENT
INMB : Nasdaq
INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference
conferences
IMPACT
SENTIMENT
INMB : Nasdaq
INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’s Disease
clinical trial
IMPACT
SENTIMENT
INMB : Nasdaq
INmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update
earnings
IMPACT
SENTIMENT
INMB : Nasdaq
INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference
conferences
IMPACT
SENTIMENT
INMB : Nasdaq
INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7
conferences earnings
IMPACT
SENTIMENT
INMB : Nasdaq
INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.
IMPACT
SENTIMENT
INMB : Nasdaq
INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease
IMPACT
SENTIMENT
INMB : Nasdaq
INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology
IMPACT
SENTIMENT
INMB : Nasdaq
INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy
conferences
Stock INMB logo
INmune Bio Inc
Nasdaq:INMB

INMB Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link

About INMB

inmune bio inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. inkmune, the company’s lead product, primes patient’s nk cells (natural killer cells) to kill cancer. inmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. by controlling residual disease, patients may live longer. using a novel mechanism of action and a precision medicine approach, inkmune therapy should enhance nk cells’ ability to eliminate residual disease.